Pluristem Therapeutics Inc.
) recently reported progress on its phase I/II clinical trial,
which is evaluating the safety and efficacy of its PLacental
eXpanded (PLX) cells in the treatment of muscle injury.
Pluristem develops placenta-based cell therapies. The cells from
placenta are derived using the company's proprietary PluriX
Safety is the primary endpoint of the study while the secondary
endpoint is the gluteal muscle function after six months.
A positive outcome from this study will enable Pluristem to
further evaluate the potential of PLX cells for this indication
along with other non-surgical injuries such as sports injuries.
Pluristem develops and manufactures cell therapy products in
collaboration with companies like United Therapeutics or through
research and clinical institutions.
Pluristem intends to develop and produce cell therapy products
for the treatment of multiple disorders using several methods of
We note that Pluristem and its partner
) entered into a licensing agreement in Jun 2011 as per which
United Therapeutics develops, markets and sells Pluristem's PLX
cells for pulmonary arterial hypertension (PAH).
Both the companies commenced a phase I study in Australia using
Pluristem's PLX cells following favorable preclinical studies in
In a significant development in Feb 2013, the US Food and Drug
Administration (FDA) granted Pluristem's PLX cells an orphan drug
status for the treatment of aplastic anemia.
) is also carrying out research on stem cells derived from the
human placenta as well as from the umbilical cord for the
treatment of different diseases.
Pluristem carries a Zacks Rank #3 (Hold). Pharma stocks, such as
) currently appear to be attractive with a Zacks Rank #2
ARRAY BIOPHARMA (ARRY): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis
PLURISTEM THERA (PSTI): Free Stock Analysis
UTD THERAPEUTIC (UTHR): Free Stock Analysis
To read this article on Zacks.com click here.